Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doripenem

FDA-approved product (injectable, intravenous), marketed as Doribax.

Registered studies
31
Lab records
52
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Doripenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Pyelonephritis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH04

Repurposing investigation

Doripenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli98.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

31registered studies name this medicine, for any condition. See them below.

Experimental

  • K. pneumoniae: measured active in 52 of 52 lab records
Open Doripenem in ChEMBL Registered studies below
Show the 52 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doripenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria

    NCT02134106 · start 2015-01

    Registered record
    Registry ID
    NCT02134106
    Conditions
    Bacteremia; Healthcare-associated Pneumonia; Ventilator-associated Pneumonia
    Interventions
    Polymyxin B; Polymyxin B + Doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2015-01
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia; Healthcare-associated Pneumonia; Ventilator-associated Pneumonia
    InterventionPolymyxin B; Polymyxin B + Doripenem
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization

    NCT01797133 · start 2013-02

    Registered record
    Registry ID
    NCT01797133
    Conditions
    All Hospitalzied Patients; No Specific Conditions Requires
    Interventions
    ID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-02
    Completion
    2013-12
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAll Hospitalzied Patients; No Specific Conditions Requires
    InterventionID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorization
    PhaseNot applicable
    Registry statusCompleted

  • Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

    NCT01595438 · start 2012-10

    Registered record
    Registry ID
    NCT01595438
    Conditions
    Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-08
    Enrolment
    598

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    PhasePhase 3
    Registry statusCompleted

  • Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

    NCT01599806 · start 2012-10

    Registered record
    Registry ID
    NCT01599806
    Conditions
    Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-08
    Enrolment
    641

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    PhasePhase 3
    Registry statusCompleted

  • A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age

    NCT01366651 · start 2012-03

    Registered record
    Registry ID
    NCT01366651
    Conditions
    Meningitis
    Interventions
    Doripenem; Doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-03
    Completion
    2012-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMeningitis
    InterventionDoripenem; Doripenem
    PhasePhase 1
    Registry statusTerminated

  • Antibiotic Concentrations Among Critically Ill Patients

    NCT01543334 · start 2012-03

    Registered record
    Registry ID
    NCT01543334
    Conditions
    Administration of Antibiotics in Intensive Care Units
    Interventions
    Blood sampling
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-04-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdministration of Antibiotics in Intensive Care Units
    InterventionBlood sampling
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic of Doripenem and Piperacillin/Tazobactam in More Than 120 kg Critically Ill Patients

    NCT01517815 · start 2012-02

    Registered record
    Registry ID
    NCT01517815
    Conditions
    Septic Shock
    Interventions
    Doripenem or Piperacillin/Tazobactam; Doripenem or Piperacillin/Tazobactam
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionDoripenem or Piperacillin/Tazobactam; Doripenem or Piperacillin/Tazobactam
    PhaseNot applicable
    Registry statusCompleted

  • Target Site Pharmacokinetics of Doripenem at Steady State in Intubated Intensive Care Patients

    NCT01414959 · start 2011-08

    Registered record
    Registry ID
    NCT01414959
    Conditions
    Pneumonia; Abdominal Infection; Urinary Tract Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-08
    Completion
    2013-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Abdominal Infection; Urinary Tract Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

    NCT01110382 · start 2010-12

    Registered record
    Registry ID
    NCT01110382
    Conditions
    Abscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain; Appendicitis; Rupture; Infection; Intestinal Perforation; Peritonitis; Ileus
    Interventions
    Doripenem; Meropenem placebo; Meropenem; Doripenem placebo; Amoxicillin/clavulanate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2013-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAbscess, Intra-Abdominal; Abdominal Abscess; Abdomen, Acute; Abdominal Pain +6 more
    InterventionDoripenem; Meropenem placebo; Meropenem; Doripenem placebo +1 more
    PhasePhase 3
    Registry statusTerminated

  • A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

    NCT01110408 · start 2010-12

    Registered record
    Registry ID
    NCT01110408
    Conditions
    Complicated Urinary Tract Infections or Pyelonephritis
    Interventions
    Doripenem; Doripenem placebo; Cefepime; Cefepime placebo; Amoxicillin/clavulanate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2013-06
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infections or Pyelonephritis
    InterventionDoripenem; Doripenem placebo; Cefepime; Cefepime placebo +1 more
    PhasePhase 3
    Registry statusTerminated

  • A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

    NCT01110421 · start 2010-12

    Registered record
    Registry ID
    NCT01110421
    Conditions
    Pneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-Associated
    Interventions
    Cefepime placebo; Cefepime; Doripenem; Doripenem placebo; Amoxicillin/clavulanate potassium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2012-03
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Bacterial; Community-Acquired Infections; Nosocomial Infection; Pneumonia, Ventilator-Associated
    InterventionCefepime placebo; Cefepime; Doripenem; Doripenem placebo +1 more
    PhasePhase 3
    Registry statusTerminated

  • Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

    NCT01281462 · start 2010-12

    Registered record
    Registry ID
    NCT01281462
    Conditions
    Urinary Tract Infections
    Interventions
    Ceftaroline fosamil and NXL104 (q8h); Ceftaroline fosamil and NXL104 (q12h); Doripenem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-07
    Enrolment
    217

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCeftaroline fosamil and NXL104 (q8h); Ceftaroline fosamil and NXL104 (q12h); Doripenem; Placebo
    PhasePhase 2
    Registry statusCompleted

  • The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia

    NCT01467648 · start 2010-10

    Registered record
    Registry ID
    NCT01467648
    Conditions
    Ventilator-Associated Pneumonia
    Interventions
    Doripenem; Doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-10
    Completion
    2011-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator-Associated Pneumonia
    InterventionDoripenem; Doripenem
    PhasePhase 4
    Registry statusCompleted

  • Target Site Pharmacokinetics of Doripenem After a Single Dose of 500mg in Healthy Volunteers Dori_MD_1

    NCT01311141 · start 2010-08

    Registered record
    Registry ID
    NCT01311141
    Conditions
    Healthy
    Interventions
    doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiondoripenem
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

    NCT01401010 · start 2010-08

    Registered record
    Registry ID
    NCT01401010
    Conditions
    Febrile Neutropenia
    Interventions
    Doripenem; doripenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-08
    Completion
    2012-02
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionDoripenem; doripenem
    PhasePhase 4
    Registry statusCompleted